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3Elsewhere in this issue, Dr. Milton Weinstein and
colleagues set out principles for good practice in
decision analytic modeling in health care evaluation
[1]. The article is the most recent in a small series
that have set out to assist both producers and users
of models in their quest for excellence or at least
adequacy. It builds on what has gone before and is
the most comprehensive and valuable to date.
As a member of the Appraisal Committee of the
National Institute for Clinical Excellence (NICE) 
in England, I am charged with fellow committee
members to form views on whether particular
health technologies (drugs, surgical procedures,
diagnostic techniques, devices, educational pro-
grams, etc.) are effective and cost-effective and
therefore whether they should be available, free of
charge. When the committee was ﬁrst formed, mod-
eling was not regarded as having an important place
in helping the committee reach decisions. Now,
after three years’ experience, its place is central,
with the majority of appraisals being informed by
models produced either by manufacturers or a
NICE-commissioned assessment team.
Models play a number of important roles. They
often enable estimation of long-term impacts of
concern (mortality, quality of life) in any therapeu-
tic area from the speciﬁc evidence of short-term efﬁ-
cacy available from clinical trials of the technology
under consideration. Typical examples of the latter
might be blood lipid levels, presence or absence of
abnormal cells, or event rates, such as frequency of
acute rejection episodes among solid organ trans-
plant recipients or frequency of second myocardial
infarctions in a group of previous sufferers. The
modeling allows consideration of likely longer-term
consequences of short-term effects as well as the
combination of a variety of impacts (for example,
from the various sequelae of diabetes).
For the committee, this facilitates comparison
between different therapeutic areas by providing
estimates of, for example, cost per quality-adjusted
life year (QALY) gained as well as those, such as
cost per acute rejection episode avoided, which
might follow relatively readily directly from clinical
trial evidence. The common currency of the cost per
QALY is extremely helpful when technologies that
are necessarily disparate are compared.
Even when data relevant to reaching a decision
are scarce, modeling has proved useful. At times it
has helped focus the committee on key parameters
in a decision so that energy can be directed toward
consideration of their likely scale. Thus, when it has
been shown that the key issue in assessing cost-
effectiveness is the quality-of-life impact of the clin-
ical changes brought about, the committee has tried
to assess whether threshold levels of gain are likely
to be achieved or not. At times it has even proved
possible to undertake supplementary collection of
evidence on just the crucial issue.
More generally, models have proved their worth
in indicating both the value of obtaining further
information and what its nature should be. On at
least one occasion, a formal value of information
analysis included with a model has led to the 
committee recommending that a technology be 
supported for a period but in such a way that the
indicated information was collected to inform a
subsequent review of the decision.
Models have become an indispensable part of the
analysis that the NICE Appraisal Committee uses
to reach many of its decisions. It is therefore crucial
that the models used are of high quality. For other
types of evidence considered by the committee,
there are in existence checklists of quality. Notably,
the work of the Cochrane Collaboration and others
has systematized the reviewing and synthesis of clin-
ical trial evidence so that we can say not only what
the evidence on a particular technology suggests is
the case but also the strength of belief we should
have in the result. We have yardsticks by which we
can judge the quality of trials. This is only gradu-
ally becoming the case for models and the article by
Weinstein and colleagues is a further step on the
road to a generally held view of what constitutes
good quality in modeling.
The Weinstein article represents the results of 
the deliberations of an ISPOR task force set up
expressly for the purpose. The group consisted of
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representatives from most of the main centers
around the world engaged in this kind of activity
on behalf of governments, industry, or both. Most
of what has been learned about modeling for the
purposes of health-care evaluation is embodied in
the representatives of these centers.
The main part of the article consists of a state-
ment of a group consensus regarding the attributes
that deﬁne a good health-care decision model,
under the headings of structure, data, and valida-
tion. The great merit of the article is that it is very
extensive in the issues it considers—covering ﬁne
detail of the internal logic and arithmetic at one
extreme to processes for justifying the use of the
particular data chosen at another. The section on
validation is a helpful development of what has
gone before and is particularly important to groups
such as NICE. There is a comfort in knowing 
that we understand why model x gives different 
predictions to model y because it reassures us that
we have grasped key issues in appraising a tech-
nology. Equally, there is comfort in knowing 
that predictions from a model have been tested as
far as possible and it has not been found wanting.
As a decision maker, the fear is that the model 
relied on ﬂoats in a world of its own with no test
in reality.
Areas for Yet Further Development
Excellent though it is, the article does not provide
a cookbook for assessing models. It provides a very
useful list of questions to ask and how to ask them,
but an analyst is clearly left to judge how much less
than perfection in one of the areas highlighted
matters to the utility of a particular model. In the
same way an analyst must judge whether a weak-
ness in design of a clinical trial is of consequence in
a particular context—for example, how limitations
in inclusion criteria affect the transferability of con-
clusions on efﬁcacy to a wider population—judg-
ments must be made about models. When is a
prediction made by a model close enough to observ-
able data? This is the art of evaluation and decision
taking and cannot be captured in a short article, if
at all. Nevertheless, the hints that judgments of this
type must be made that surface obliquely in the
Weinstein article are welcome and deserve to be
reinforced.
From the point of view of a user of models on
the NICE Appraisal Committee, there are three par-
ticular directions in which commentary could use-
fully be strengthened. First, in common with all
economic evaluations, the speciﬁcation of the ques-
tion is crucial, as is making it clear to users of the
model what that question is. Thus, a model may
give some clear messages about the potential cost-
effectiveness of a technology, but the (implicit) ques-
tion being addressed is not relevant to any policy or
clinical decisions being contemplated. This suggests
that the process of determining exactly what ques-
tion should be addressed is itself something which
could and should be made systematic and trans-
parent. Although Weinstein and colleagues in their
discussion of model structures touch on it, this part
of process, which is crucial to decision making, 
is deserving of further attention. A section on the
exact question being addressed, and why, is a must
in reports which accompany models.
Second, and related, the comparators that are
included in the model really matter. Again, the dis-
cussion of the process by which comparators should
be chosen is fairly slight, but if comparators are
included that are not relevant in a particular deci-
sion context, the model may be worthless. It is easy
to pass off the choice of comparator as an issue of
data availability. It is not; it is an issue of the deci-
sion to be informed. Differences between clinical
practices in different countries (and even different
hospitals in the same countries) may render models
that are valuable in one national context useless 
in another. The question has arisen at times in the
NICE appraisal context of the relevance of models
developed outside the United Kingdom. There may
be many difﬁculties in using models developed over-
seas. Few are insuperable but inclusion only of com-
parators which are not relevant in the United
Kingdom is one of them.
Third, the issue of transparency is key. Weinstein
and colleagues consider this but only brieﬂy. During
the NICE appraisal process there is a real reluctance
to trust a model if it cannot be examined in detail,
even if it has already been published and subject to
peer review. Not all journals have a reliable peer
review process for models and not all require the
availability of the full model in electronic form. At
the heart of this mistrust is a concern that parties
to the NICE process might deliberately or inadver-
tently mislead the committee on cost-effectiveness
estimates through misspeciﬁcation of the model in
some way. 
There are, of course, understandable reasons
why models might be withheld, for example,
because they contain data that are commercial in
conﬁdence. This is certainly an issue for NICE.
However, equally important is the interest of acad-
emics in intellectual property rights in a model. This
is touched on only brieﬂy by Weinstein and col-
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leagues, but must be tackled or models will continue
to be published with readers unable to check in
detail what has been done.
A major part of the answer to the transparency
problem may lie with the editorial policies of acad-
emic journals. If journals insist on true transparency
and availability of models for examination before
modeling papers are published, this may force the
issue. A problem that journals have had until
recently has been the absence of standards against
which submitted models may be judged. Weinstein
and colleagues have taken on those standards a
further stage from those published before and give
editors and decision makers alike a valuable tool in
assessing the merits of any particular model. The
article is greatly to be welcomed.
Reference
1 Weinstein MC, O’Brien B, Hornberger J, et al. Prin-
ciples of good practice for decision analytic model-
ing in health-care evaluation: report of the ISPOR
Task Force on Good Research Practices—Modeling
Studies. Value Health 2003;6:9–17.
